Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer

Affiliations

Haoran Feng: Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
Kun Liu: Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
Xiaonan Shen: Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Juyong Liang: Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
Changgang Wang: Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
Weihua Qiu: Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
Xi Cheng: Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
Ren Zhao: Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41419-020-03208-z